Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 26

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 26
---
 we expand. In addition, we compete with our competitors in acquiring technologies and technology licenses complementary to our
products or procedures or advantageous to our business. If we are unable to compete successfully against our existing or potential competitors,
our business, financial condition and results of operations may be adversely affected, and we may not be able to grow at our expected
rate, if at all. See “Business – Competition” below.

We expect to derive most of our revenues from the sales of our GelrinC. Our inability to successfully commercialize this product candidate or any subsequent decline in demand for this product candidate, could severely harm our ability to generate revenues.

We are currently dependent
on the successful commercialization of GelrinC to generate revenues. As a result, factors adversely affecting our ability to successfully
commercialize, or the pricing of or demand for, this product could have a material adverse effect on our financial condition and results
of operations. If we are unable to successfully commercialize or create market demand for GelrinC, we will have limited ability to generate
revenues.

Furthermore, we may be vulnerable
to fluctuations in demand for GelrinC. Such fluctuations in demand may be due to many factors, many of which are beyond our control,
including, among others:

| ● | market                                                                         
 acceptance of a new product, including healthcare professionals’ and patients’ 
 preferences;                                                                   |

<div align='center'>19</div>

| ● | market acceptance of the                    
 clinical safety and performance of GelrinC; |

| ● | development of similarly                    
 cost-effective products by our competitors; |

| ● | development delays of GelrinC; |

| ● | adverse medical side effects                                                                   
 suffered by patients using GelrinC, whether actually resulting from the use of GelrinC or not; |

| ● | changes in regulatory policies     
 toward tissue repair technologies; |

| ● | changes in regulatory approval,                       
 clearance requirements and licensure for our product; |

| ● | third-party claims of intellectual 
 property infringement;             |

| ● | budget constraints and                                                                       
 the availability of reimbursement or insurance coverage from third-party payors for GelrinC; |

| ● | adverse responses from                                     
 certain of our competitors to the offering of GelrinC; and |

| ● | the shelf life of GelrinC. |

If healthcare professionals do not recommend our product to their patients, GelrinC may not achieve market acceptance and we may not become profitable.

If healthcare professionals,
including physicians, do not recommend or prescribe our